All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Data Compilation Highlights Potential of SON-1010 to Enhance Therapeutic Efficacy in Solid Tumors

March 5th 2025

SON-1010 is being investigated for its potential to improve outcomes in solid tumors.

Ensartinib Looks to Find a Place in ALK+ NSCLC Paradigm Alongside Approved TKIs

March 5th 2025

Alberto Chiappori, MD, details how to select between ensartinib and approved ALK TKIs for NSCLC, as well as considerations with ensartinib’s FDA approval.

T-DXd’s Role Expands Into HER2-Low/-Ultralow Metastatic Breast Cancer, Reinforcing Need for Enhanced HER2 Testing

March 5th 2025

Aditya Bardia, MD, MPH, FASCO, discusses how the FDA approval of T-DXd for HER2-low/-ultralow metastatic breast cancer has affected the treatment paradigm.

SWOG S1815 Shows Need for Subgroup-Specific Triplet Chemotherapy Assessment in Biliary Tract Cancer

March 5th 2025

Rachna Shroff, MD, MS, FASCO, discusses the potential role for nab-paclitaxel plus gemcitabine and cisplatin in select patients with biliary tract cancers.

Nogapendekin Alfa Inbakicept/CAR-NK Wins FDA RMAT Designation for Lymphopenia Reversal in Metastatic Pancreatic Cancer

March 5th 2025

The FDA granted RMAT designation to nogapendekin alfa inbakicept/CAR-NK for lymphopenia reversal in patients with advanced or metastatic pancreatic cancer.

Norway Grants Marketing Authorization to Illuccix PSMA-PET Imaging Agent in Prostate Cancer

March 5th 2025

NOMA has approved the PET imaging agent for the identification of PSMA-positive lesions in patients with prostate cancer.

Tumor-Agnostic Approvals of T-DXd and Repotrectinib Carry the Field Forward

March 5th 2025

Clinicians parse through the impacts of tumor-agnostic FDA approvals, examining T-DXd and repotrectinib's 2024 approvals in particular.

ARX788 Displays Activity in HER2+ Advanced Breast Cancer

March 5th 2025

ARX788 was safe and effective in HER2+ advanced breast cancer after disease progression on 1 line of a trastuzumab-based regimen.

Nivolumab/Ipilimumab Combination Represents Potential Standard-of-Care Shift in MSI-H/dMMR mCRC

March 5th 2025

Thierry André, MD, discusses findings from the phase 3 CheckMate 8HW trial of nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Tivozanib Preserves QOL From Baseline to Week 24 in ICI-Pretreated RCC

March 4th 2025

Katy Beckermann, MD, PhD, discusses key findings from a PRO analysis of tivozanib/nivolumab vs tivozanib alone in ICI-pretreated RCC.

Toxicity, Sequencing Considerations Are Key for Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer

March 4th 2025

Brandon G. Smaglo, MD, FACP, discusses upfront treatment considerations for patients with metastatic pancreatic cancer.

Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS

March 4th 2025

Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.

Fox Chase Cancer Center’s Erin K. Tagai Receives Prevent Cancer Foundation Grant to Develop Tool to Assist Patients Awaiting Genetic Testing Results

March 4th 2025

Erin K. Tagai, PhD, MPH, has received a grant from the Prevent Cancer Foundation to fund development of a ChatBot for patients receiving genetic testing results.

FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease

March 4th 2025

The FDA has approved 2 denosumab biosimilars for all indications of their respective reference medications.

FDA Grants Orphan Drug Designation to Bexmarilimab for Myelodysplastic Syndromes

March 4th 2025

The FDA has granted orphan drug designation to bexmarilimab for myelodysplastic syndromes.

Combination Regimens Expand CLL Treatment Paradigm

March 4th 2025

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Lisaftoclax Plus Azacitidine Shows Clinical Activity and Manageable Safety in Higher-Risk MDS

March 4th 2025

Lisaftoclax plus azacitidine demonstrated clinical activity and was safe in higher-risk MDS.

FDA Approves First-Line Tislelizumab Plus Chemotherapy for Unresectable or Metastatic ESCC

March 4th 2025

The FDA has approved tislelizumab-jsgr plus chemotherapy for frontline use in adult patients with advanced esophageal squamous cell carcinoma and PD-L1 expression.

Quizartinib Plus Chemotherapy Is Set to Be Evaluated in FLT3-ITD-Negative AML in Phase 3 Trial

March 3rd 2025

Quizartinib with 7+3 chemotherapy was safe and effective in patients with FLT3-ITD–negative AML, leading to the initiation of the phase 3 QuANTUM-Wild trial.

Disparities in RCC Trial Access Illuminate the Need for Global Scientific Collaboration

March 3rd 2025

Regina Barragan-Carrillo, MD, discusses a study of RCC clinical trial availability and barriers to opening RCC clinical trials in lower-income countries.